Evidence map›Paper›PMID 26328888›Full record

ArticleBMC genomics2015

Integrative analysis of the microRNA-mRNA response to radiochemotherapy in primary head and neck squamous cell carcinoma cells.

Isolde Summerer, Julia Hess, Adriana Pitea, Kristian Unger, Ludwig Hieber, Martin Selmansberger, Kirsten Lauber, Horst Zitzelsberger

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Isolde SummererResearch Unit Radiation Cytogenetics, Helmholtz Center Munich, Ingolstaedter Landstr.1, 85764, Neuherberg, Germany. isolde.summerer@helmholtz-muenchen.de.
Julia HessResearch Unit Radiation Cytogenetics, Helmholtz Center Munich, Ingolstaedter Landstr.1, 85764, Neuherberg, Germany. julia.hess@helmholtz-muenchen.de.
Adriana PiteaResearch Unit Radiation Cytogenetics, Helmholtz Center Munich, Ingolstaedter Landstr.1, 85764, Neuherberg, Germany. adriana.pitea@helmholtz-muenchen.de.
Kristian UngerResearch Unit Radiation Cytogenetics, Helmholtz Center Munich, Ingolstaedter Landstr.1, 85764, Neuherberg, Germany. unger@helmholtz-muenchen.de.
Ludwig HieberResearch Unit Radiation Cytogenetics, Helmholtz Center Munich, Ingolstaedter Landstr.1, 85764, Neuherberg, Germany. ludwig.hieber@helmholtz-muenchen.de.
Martin SelmansbergerResearch Unit Radiation Cytogenetics, Helmholtz Center Munich, Ingolstaedter Landstr.1, 85764, Neuherberg, Germany. martin.selmansberger@helmholtz-muenchen.de.
Kirsten LauberClinical Cooperation Group 'Personalized Radiotherapy of Head and Neck Cancer', Helmholtz Center Munich, Ingolstaedter Landstr. 1, 85764, Neuherberg, Germany. kirsten.lauber@med.uni-muenchen.de.
Horst ZitzelsbergerResearch Unit Radiation Cytogenetics, Helmholtz Center Munich, Ingolstaedter Landstr.1, 85764, Neuherberg, Germany. zitzelsberger@helmholtz-muenchen.de.
Helmholtz Zentrum München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHead and neck squamous cell carcinoma (HNSCC) is a very heterogeneous disease resulting in huge differences in the treatment response. New individualized therapy strategies including molecular targeting might help to improve treatment success. In order to identify potential targets, we developed a HNSCC radiochemotherapy cell culture model of primary HNSCC cells derived from two different patients (HN1957 and HN2092) and applied an integrative microRNA (miRNA) and mRNA analysis in order to gain information on the biological networks and processes of the cellular therapy response. We further identified potential target genes of four therapy-responsive miRNAs detected previously in the circulation of HNSCC patients by pathway enrichment analysis.

resultsThe two primary cell cultures differ in global copy number alterations and P53 mutational status, thus reflecting heterogeneity of HNSCC. However, they also share many copy number alterations and chromosomal rearrangements as well as deregulated therapy-responsive miRNAs and mRNAs. Accordingly, six common therapy-responsive pathways (direct P53 effectors, apoptotic execution phase, DNA damage/telomere stress induced senescence, cholesterol biosynthesis, unfolded protein response, dissolution of fibrin clot) were identified in both cell cultures based on deregulated mRNAs. However, inflammatory pathways represented an important part of the treatment response only in HN1957, pointing to differences in the treatment responses of the two primary cultures. Focused analysis of target genes of four therapy-responsive circulating miRNAs, identified in a previous study on HNSCC patients, revealed a major impact on the pathways direct P53 effectors, the E2F transcription factor network and pathways in cancer (mainly represented by the PTEN/AKT signaling pathway).

conclusionsThe integrative analysis combining miRNA expression, mRNA expression and the related cellular pathways revealed that the majority of radiochemotherapy-responsive pathways in primary HNSCC cells are related to cell cycle, proliferation, cell death and stress response (including inflammation). Despite the heterogeneity of HNSCC, the two primary cell cultures exhibited strong similarities in the treatment response. The findings of our study suggest potential therapeutic targets in the E2F transcription factor network and the PTEN/AKT signaling pathway.

Indexed as

ChemoradiotherapyAgedAged, 80 and overCarcinoma, Squamous CellCell Line, TumorCluster AnalysisFemaleGene Expression Regulation, NeoplasticGene Regulatory NetworksHead and Neck NeoplasmsHumansMaleMicroRNAsReproducibility of ResultsRNA, MessengerSignal TransductionMicroRNAsRNA, Messenger

Identifiers

PMID26328888
PMCPMC4557600
OpenAlexW2130822550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.